7 research outputs found
Direct and cytokine-mediated effects of albumin-fused growth hormone, TV-1106, on CYP enzyme expression in human hepatocytes in vitro
Some biologics can modulate cytokines that may lead to changes in expression of drugmetabolizing
enzymes and cause drug-drug interactions (DDI). DDI potential of TV-
1106—an albumin-fused growth hormone (GH)—was investigated. In this study, human
blood was exposed to recombinant human growth hormone (rhGH) or TV-1106, followed
by isolation of the plasma and its application to human hepatocytes. While the
treatment of blood with rhGH increased multiple cytokines, treatment of blood with
TV-1106 had no effect on any of the nine cytokines tested. The interleukin (IL)-6 concentration
was higher in the rhGH then in the TV-1106-treated plasma (P < .05). While
rhGH had little or no effect on CYP1A2 or CYP2C19 mRNA but increased CYP3A4
mRNA twofold, TV-1106 had little or no effect on cytochrome P450 (CYP) mRNAs in
hepatocytes. Although the plasma from rhGH-treated blood lowered CYP1A2 activity,
the TV-1106 plasma had no effect on CYP activities. The CYP1A2 activity was lower in
the rhGH- then in the TV-1106-plasma treated hepatocytes (P < .05). The results indicated
that fusing GH with albumin made TV-1106 an unlikely participant of CYP1A2,
CYP2C19 or CYP3A4-facilitated, direct or cytokine-driven DDI.The authors would like to thank scientists in the Scientific Operations
at Sekisui XenoTech for their technical assistance
Interaction between the glutamate transporter GLT1b and the synaptic PDZ domain protein PICK1
This is the published version. Copyright WileySynaptic plasticity is implemented by the interaction of glutamate receptors with PDZ domain proteins. Glutamate transporters provide the only known mechanism of clearance of glutamate from excitatory synapses, and GLT1 is the major glutamate transporter. We show here that GLT1 interacts with the PDZ domain protein PICK1, which plays a critical role in regulating the expression of glutamate receptors at excitatory synapses. A yeast two-hybrid screen of a neuronal library using the carboxyl tail of GLT1b yielded clones expressing PICK1. The GLT1b C-terminal peptide bound to PICK1 with high affinity (Ki = 6.5 ± 0.4 μm) in an in vitro fluorescence polarization assay. We also tested peptides based on other variants of GLT1 and other glutamate transporters. GLT1b co-immunoprecipitated with PICK1 from rat brain lysates and COS7 cell lysates derived from cells transfected with plasmids expressing PICK1 and GLT1b. In addition, expression of GLT1b in COS7 cells changed the distribution of PICK1, bringing it to the surface. GLT1b and PICK1 co-localized with each other and with synaptic markers in hippocampal neurons in culture. Phorbol ester, an activator of protein kinase C (PKC), a known PICK1 interactor, had no effect on glutamate transport in rat forebrain neurons in culture. However, we found that exposure of neurons to a myristolated decoy peptide with sequence identical to the C-terminal sequence of GLT1b designed to block the PICK1–GLT1b interaction rendered glutamate transport into neurons responsive to phorbol ester. These results suggest that the PICK1–GLT1b interaction regulates the modulation of GLT1 function by PKC.The authors are grateful to Sara Vasquez who provided excellent technical assistance in preparing the neuronal cultures. In addition, we are grateful for helpful discussions with Drs Gabriel Corfas, Michael Berne and Michael Robinson, to Dr Tom Schwarz for reading an early version of this manuscript, and to Dr Jeff Rothstein for providing an anti-cGLT1a antibody. We are also indebted to Dr Robinson for providing us with a detailed protocol for the biotinylation studies. This work was funded by grants from the Ron Shapiro Charitable Foundation (P.A.R.), the Muscular Dystrophy Association (P.A.R.), and National Institutes of Health research grant NS 40753 and a Mental Retardation Core Grant HD18655
Interaction between the glutamate transporter GLT1b and the synaptic PDZ domain protein PICK1
Synaptic plasticity is implemented by the interaction of glutamate receptors with PDZ domain proteins. Glutamate transporters provide the only known mechanism of clearance of glutamate from excitatory synapses, and GLT1 is the major glutamate transporter. We show here that GLT1 interacts with the PDZ domain protein PICK1, which plays a critical role in regulating the expression of glutamate receptors at excitatory synapses. A yeast two-hybrid screen of a neuronal library using the carboxyl tail of GLT1b yielded clones expressing PICK1. The GLT1b C-terminal peptide bound to PICK1 with high affinity (K(i) = 6.5 ± 0.4 μm) in an in vitro fluorescence polarization assay. We also tested peptides based on other variants of GLT1 and other glutamate transporters. GLT1b co-immunoprecipitated with PICK1 from rat brain lysates and COS7 cell lysates derived from cells transfected with plasmids expressing PICK1 and GLT1b. In addition, expression of GLT1b in COS7 cells changed the distribution of PICK1, bringing it to the surface. GLT1b and PICK1 co-localized with each other and with synaptic markers in hippocampal neurons in culture. Phorbol ester, an activator of protein kinase C (PKC), a known PICK1 interactor, had no effect on glutamate transport in rat forebrain neurons in culture. However, we found that exposure of neurons to a myristolated decoy peptide with sequence identical to the C-terminal sequence of GLT1b designed to block the PICK1–GLT1b interaction rendered glutamate transport into neurons responsive to phorbol ester. These results suggest that the PICK1–GLT1b interaction regulates the modulation of GLT1 function by PKC
Central Nervous System Relapse in Adults with Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis
Abstract Primary sclerosing cholangitis (PSC) is characterized by progressive biliary inflammation and fibrosis. Although gut commensals are associated with PSC, their causative roles and therapeutic strategies remain elusive. Here we detect abundant Klebsiella pneumoniae (Kp) and Enterococcus gallinarum in fecal samples from 45 PSC patients, regardless of intestinal complications. Carriers of both pathogens exhibit high disease activity and poor clinical outcomes. Colonization of PSC-derived Kp in specific pathogen-free (SPF) hepatobiliary injury-prone mice enhances hepatic Th17 cell responses and exacerbates liver injury through bacterial translocation to mesenteric lymph nodes. We developed a lytic phage cocktail that targets PSC-derived Kp with a sustained suppressive effect in vitro. Oral administration of the phage cocktail lowers Kp levels in Kp-colonized germ-free mice and SPF mice, without off-target dysbiosis. Furthermore, we demonstrate that oral and intravenous phage administration successfully suppresses Kp levels and attenuates liver inflammation and disease severity in hepatobiliary injury-prone SPF mice. These results collectively suggest that using a lytic phage cocktail shows promise for targeting Kp in PSC